The PKC inhibitor AEB071 may be a therapeutic option for psoriasis

• Published in: The Journal of clinical investigation Vol. 118; no. 9; pp. 3151 - 3159
• Main Authors: Skvara, Hans, Dawid, Markus, Kleyn, Elise, Wolff, Barbara, Meingassner, Josef G., Knight, Hilary, Dumortier, Thomas, Kopp, Tamara, Fallahi, Nasanin, Stary, Georg, Burkhart, Christoph, Grenet, Olivier, Wagner, Juergen, Hijazi, Youssef, Morris, Randall E., McGeown, Claire, Rordorf, Christiane, Griffiths, Christopher E.M., Stingl, Georg, Jung, Thomas
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.09.2008
• Subjects: Animals; Antigens; Autoimmune diseases; Biomedical research; Care and treatment; Cell growth; Cytokines; Dendritic cells; Dermatitis; Dermatitis - drug therapy; Diagnosis; Dose-Response Relationship, Drug; Double-Blind Method; Health aspects; Humans; Hypersensitivity - drug therapy; Interleukin-2 - biosynthesis; Kinases; Lymphocyte Activation - drug effects; Lymphocytes; Lymphocytes - drug effects; Physiological aspects; Placebos; Protein Isoforms; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Protein kinases; Psoriasis; Psoriasis - drug therapy; Rats; Skin - drug effects; United States

PKC isoforms tau, alpha, and beta play fundamental roles in the activation of T cells and other immune cell functions. Here we show that the PKC inhibitor AEB071 both abolishes the production of several cytokines by activated human T cells, keratinocytes, and macrophages in vitro and inhibits an acu...